India’s first indigenous CAR-T cell therapy, NexCAR19, developed by ImmunoACT, an IIT Bombay spin-off, marks a major leap in ...
During the July-September quarter, Metropolis’s B2B business reported 33 per cent growth, while B2C revenue inched up 16 per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback